Evidence map›Paper›PMID 22527714›Full record

ArticleCellular and molecular life sciences : CMLS2012

Bioportide: an emergent concept of bioactive cell-penetrating peptides.

John Howl, Sabine Matou-Nasri, David C West, Michelle Farquhar, Jiřina Slaninová, Claes-Göran Ostenson, Matjaz Zorko, Pernilla Ostlund, Shant Kumar, Ulo Langel and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Designed Multifunctional Peptides for Intracellular Targets.Antibiotics (Basel, Switzerland) · 2022
    Review
  5. Cell-Penetrating Peptides.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 4 countries.

John HowlResearch Institute in Healthcare Science, School of Applied Sciences, University of Wolverhampton, Wolverhampton, WV1 1LY, UK. J.Howl@wlv.ac.uk
Sabine Matou-Nasri
David C West
Michelle Farquhar
Jiřina Slaninová
Claes-Göran Ostenson
Matjaz Zorko
Pernilla Ostlund
Shant Kumar
Ulo Langel
Jane McKeating
Sarah Jones
Stockholm University · SEUniversity of Birmingham · GBUniversity of Wolverhampton · GBCzech Academy of Sciences · CZKarolinska Institutet · SEManchester Metropolitan University · GBUniversity of Liverpool · GBUniversity of Ljubljana · SIUniversity of Manchester · GB

Funding

Medical Research Council G0400802Medical Research Council G0801976
6 · The paper itself

Abstract

Cell-penetrating peptides (CPPs) have proven utility for the highly efficient intracellular delivery of bioactive cargoes that include peptides, proteins, and oligonucleotides. The many strategies developed to utilize CPPs solely as pharmacokinetic modifiers necessarily requires them to be relatively inert. Moreover, it is feasible to combine one or multiple CPPs with bioactive cargoes either by direct chemical conjugation or, more rarely, as non-covalent complexes. In terms of the message-address hypothesis, this combination of cargo (message) linked to a CPP (address) as a tandem construct conforms to the sychnological organization. More recently, we have introduced the term bioportide to describe monomeric CPPs that are intrinsically bioactive. Herein, we describe the design and biochemical properties of two rhegnylogically organized monometic CPPs that collectively modulate a variety of biological and pathophysiological phenomena. Thus, camptide, a cell-penetrant sequence located within the first intracellular loop of a human calcitonin receptor, regulates cAMP-dependent processes to modulate insulin secretion and viral infectivity. Nosangiotide, a bioportide derived from endothelial nitric oxide synthase, potently inhibits many aspects of the endothelial cell morphology and movement and displays potent anti-angiogenic activity in vivo. We conclude that, due to their capacity to translocate and target intracellular signaling events, bioportides represent an innovative generic class of bioactive agents.

Indexed as

Drug Delivery SystemsEndocytosisAnimalsAortaAstrocytomaBrainCattleCell Membrane PermeabilityCell-Penetrating PeptidesCells, CulturedChemotaxisChorioallantoic MembraneCyclic AMPDermisDiabetes Mellitus, Type 2Endothelium, VascularCell-Penetrating PeptidesCyclic AMPInsulin

Identifiers

PMID22527714
PMCPMC11114504
OpenAlexW2149587981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.